Healthcare Industry News:  ChondroGene 

Diagnostics Personnel

 News Release - May 10, 2006

ChondroGene appoints David Tyler Director, Product Development and Quality Assurance

TORONTO, May 10 (HSMN NewsFeed) - ChondroGene Limited (TSX Venture: CDG ) reported today that David J. Tyler has joined ChondroGene as Director, Product Development and Quality Assurance. He will focus on advancing the Company's product development and manufacturing capabilities, and the implementation and management of the Company's quality system as the Company enters the commercialization process for its products. The Company's initial product will be ColonSentry(TM), a blood-based test for the detection of precancerous polyps and colon cancer.



Mr. Tyler has extensive experience in the development and manufacturing of complex molecular diagnostic products and reagents, having worked most recently with Prodesse Inc. and Third Wave Technologies. He was instrumental in establishing and managing product development and GMP manufacturing operations as well as obtaining ISO 13485 certification at these companies.

Prior to that, he held various research and management positions at the Howard Hughes Medical Institute at the University of California, Berkeley, the University of California, San Francisco and the Lawrence Berkeley National Laboratories.

Mr. Tyler has a BA in Biochemistry and an MS in Microbiology, both from the University of California, Berkley.

"We are pleased to have Dave join our team. His background and expertise in quality systems, product development and manufacturing will be instrumental as we continue to implement commercialization of our lead product ColonSentry," stated K. Wayne Marshall, MD, PhD, President and CEO of ChondroGene. "This is a pivotal time for ChondroGene, as we expand our capabilities in order to take our products from the research lab to the market. To this end, we are committed to building an experienced molecular diagnostics team. Dave's appointment continues to build on the momentum initiated with the hiring of Dr. Daniel H. Farkas as VP of Clinical Diagnostics last November."

About ChondroGene

ChondroGene is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. ChondroGene is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on ChondroGene, visit www.ChondroGene.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.




Source: ChondroGene

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.